CTNM vs CTXR

Contineum Therapeutics, Inc. vs Citius Pharmaceuticals, Inc. — Valuation Comparison 2026

CTNM

Biotechnology
Contineum Therapeutics, Inc.
Quality
4.6
out of 10
Value Trap
12
SAFE
Price
$13.31
Last close
Models
7/13
Active
VS

CTXR

Biotechnology
Citius Pharmaceuticals, Inc.
Quality
3.0
out of 10
Value Trap
30
LOW
Price
$0.65
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType CTNM Fair ValueCTNM Upside CTXR Fair ValueCTXR Upside
Bayesian DCF Intrinsic $0.26 -98.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $4.05 -69.6% $0.33 -53.3%
Dynamic NAV Asset-Based $3.43 -74.0% $0.11 -84.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CTNM vs CTXR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CTNM vs CTXR — Which Stock Is More Undervalued?

CTNM scores higher with a 4.6/10 quality rating vs CTXR's 3.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Contineum Therapeutics, Inc. (CTNM) and Citius Pharmaceuticals, Inc. (CTXR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CTNM currently trades at $13.31 with a QOC of 4.6/10, while CTXR trades at $0.65 with a QOC of 3.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).